Renal failure. Acute renal failure, unspecified
Conditions
Interventions
Intervention 1: 10 unit crayopercipitat transfusion on day of biopsy in group 1. Intervention 2: Oral administration of conjugated estrogen 1.25 mg every 8 hours for 5 days before biopsy in Group 2.
Prevention
10 unit crayopercipitat transfusion on day of biopsy in group 1
Oral administration of conjugated estrogen 1.25 mg every 8 hours for 5 days before biopsy in Group 2
Sponsors
Research Deputy of Ahvaz University of Medical Science and Health science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with renal insufficiency (creatinine greater than 3 mg/dL) who are candidates for biopsy Exclusion criteria: 1.Pregnant women, or women who suspect pregnancy and ways to avoid becoming pregnant to leave have 2.Lactating women 3.Patients with a history of thromboembolism 4.Any of the patients treated with anticoagulant or platelet aggregation inhibitors such as warfarin, heparin, enoxaparin, Ticlopidine, clopidogrel, and statins and their agents can not be stopped 5.Patients who are treated with NSAIDs and their agents can not be interrupted for any reason 6.Patientswho have clotting disorders (such as patients with hemophilia) or in the laboratory of PT> 14, PTT> 35, or INR> 1.5 7.Patients who were under a regime of hard power (such as prolonged fasting or water treatment) and lack of essential Elements, vitamins such as vitamin C or K in the body there 8.Patients who have blood pressure higher than 160/100,before the biopsy 9.Patients with a creatinine level is less than 3 milligrams per deciliter 10.Patients who are suffering from liver cirrhosis. 11.Patients with platelet count less than 100,000 12.Patients who have cysts in both kidney 13.Patients who have undergone kidney transplant 14.Patients who are diagnosed with breast cancer 15.Patients who have a history of stroke and myocardial infarction 16.Patients who are unexplained uterine bleeding 17.Patients who have a history of sensitivity to estrogen compounds
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemodynamic change. Timepoint: Day of biopsy and next day. Method of measurement: Blood pressure and pulse rate control and orthostatic change.;Hemoglobin level. Timepoint: One day before biopsy and every 8 time after biopsy for 24 hour. Method of measurement: Hemoglobin level control.;Hematuria. Timepoint: Day of biopsy and next day. Method of measurement: Urine Analysis.;Biopsy site hematoma. Timepoint: Day of biopsy and next day. Method of measurement: Ultrasound.;Bleeding Time. Timepoint: Day of biopsy and next day. Method of measurement: Bleeding Time test with lancet. | — |
Secondary
| Measure | Time frame |
|---|---|
| Major bleeding. Timepoint: Day of biopsy and next day. Method of measurement: Hemodynamic change,The need for blood transfusion,Surgery. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. kaveh ebadi borna
Ahvaz Jondishapour University of Medical Science and Health Science
Outcome results
None listed